ID   HCT 116_6244R
AC   CVCL_C3GI
SY   H6244-R; H6244-R1; HCT116R_6244R
DR   cancercelllines; CVCL_C3GI
DR   GEO; GSM3591762
DR   Wikidata; Q114311571
RX   PubMed=21447798;
RX   PubMed=31048689;
CC   Population: Caucasian.
CC   Selected for resistance to: ChEBI; CHEBI_90227; Selumetinib (AZD6244).
CC   Sequence variation: Mutation; HGNC; HGNC:173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; HGNC:1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; HGNC:1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; HGNC:2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; HGNC:3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; HGNC:3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; HGNC:6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; HGNC:8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; HGNC:9277; PPM1D; Simple; p.Leu450Ter (c.1349delT) (p.Leu450fs) (c.1344delT); Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; HGNC:11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line).
CC   Omics: Transcriptomics; RNAseq.
CC   Derived from site: In situ; Colon; UBERON=UBERON_0001155.
DI   NCIt; C4910; Colon carcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_0291 ! HCT 116
SX   Male
AG   48Y
CA   Cancer cell line
DT   Created: 22-09-22; Last updated: 10-04-25; Version: 7
//
RX   PubMed=21447798; DOI=10.1126/scisignal.2001752;
RA   Little A.S., Balmanno K., Sale M.J., Newman S., Dry J.R., Hampson M.,
RA   Edwards P.A.W., Smith P.D., Cook S.J.;
RT   "Amplification of the driving oncogene, KRAS or BRAF, underpins
RT   acquired resistance to MEK1/2 inhibitors in colorectal cancer cells.";
RL   Sci. Signal. 4:Ra17.1-Ra17.15(2011).
//
RX   PubMed=31048689; DOI=10.1038/s41467-019-09438-w; PMCID=PMC6497655;
RA   Sale M.J., Balmanno K., Saxena J., Ozono E., Wojdyla K.,
RA   McIntyre R.E., Gilley R., Woroniuk A., Howarth K.D., Hughes G.,
RA   Dry J.R., Arends M.J., Caro P., Oxley D., Ashton S., Adams D.J.,
RA   Saez-Rodriguez J., Smith P.D., Cook S.J.;
RT   "MEK1/2 inhibitor withdrawal reverses acquired resistance driven by
RT   BRAF(V600E) amplification whereas KRAS(G13D) amplification promotes
RT   EMT-chemoresistance.";
RL   Nat. Commun. 10:2030.1-2030.22(2019).
//